Jefferies Healthcare Conference Replay

Watch


This link will work for 90 days from the original presentation date.

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Latest Annual Report

For Fiscal Year Ending Dec 31, 2022

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies.

Investor Contact Information

Company

Pieris Pharmaceuticals, Inc.
225 Franklin St., Floor 26
Boston, MA 02110
USA
T: +1-857-246-8998
info@pieris.com

Investor Relations

T: +1-857-246-8998
investors@pieris.com

Transfer Agent

Computershare
P.O. Box 43006
Providence RI 02940-3078
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)
web.queries@computershare.com
www.computershare.com/investor

Courier Delivery
150 Royall St.
Suite 101
Canton, MA 02021